Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab

• R. A. Manneh Kopp ^[1] ; J. M. Sepúlveda-Sánchez ^[1] ; Y. Ruano ^[1] ; O. Toldos ^[1] ; A. Pérez Núñez ^[1] ; D. Cantero ^[1] ; A. Hilario ^[1] ; A. Ramos ^[1] ; G. de Velasco ^[1] ; P. Sánchez-Gómez ^[2] ; A. Hernández-Laín ^[1]
  1. [1] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  2. [2] Neuro-Oncology UnitHealth Institute Carlos III
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 21, Nº. 10, 2019, págs. 1413-1423
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background Some phase 2 trials had reported encouraging progression-free survival with Bevacizumab in monotherapy or combined with chemotherapy in glioblastoma. However, phase 3 trials showed a significant improvement in progression free survival without a benefit in overall survival. To date, there are no predictive biomarker of response for Bevacizumab in glioblastoma.

    Methods We used Immunochemical analysis on tumor samples and pretreatment and post-treatment perfusion-MRI to try to identify possible predictive angiogenesis-related biomarkers of response and survival in patients with glioblastoma treated with bevacizumab in the first recurrence. We analyzed histological parameters: vascular proliferation, mitotic number and Ki-67 index; molecular factors: MGMT promoter methylation, EGFR amplification and EGFR variant III; immunohistochemical: MET, Midkine, HIF1, VEGFA, VEGF-R2, CD44, Olig2, microvascular area and microvascular density; and radiological: rCBV.

    Results In the statistical analysis, no significant correlation of any histological, molecular, microvascular or radiological parameters could be demonstrated with the response rate, PFS or OS with bevacizumab treatment.

    Conclusion Unfortunately, in this histopathological, molecular, immunohistochemical and neuroradiological study we did not find any predictive biomarker of response or survival benefit for Bevacizumab in glioblastoma.